Cargando…
Inhibitory Effects of HangAmDan-B1 (HAD-B1) Combined With Afatinib on H1975 Lung Cancer Cell–Bearing Mice
Epidermal growth factor receptor mutation-positive non–small cell lung cancer is cared for mainly by target therapeutics in the clinical treatment at present. We investigated the antitumor effect of HangAmDan-B1 (HAD-B1) combined with afatinib on H1975 (L858R/T790M double mutation) lung cancer cells...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419252/ https://www.ncbi.nlm.nih.gov/pubmed/30866688 http://dx.doi.org/10.1177/1534735419830765 |
_version_ | 1783403908142465024 |
---|---|
author | Kang, Hwa Jeong Kim, Jeehye Cho, Seong Hyeok Park, So-Jung Yoo, Hwa-Seung Kang, In-Cheol |
author_facet | Kang, Hwa Jeong Kim, Jeehye Cho, Seong Hyeok Park, So-Jung Yoo, Hwa-Seung Kang, In-Cheol |
author_sort | Kang, Hwa Jeong |
collection | PubMed |
description | Epidermal growth factor receptor mutation-positive non–small cell lung cancer is cared for mainly by target therapeutics in the clinical treatment at present. We investigated the antitumor effect of HangAmDan-B1 (HAD-B1) combined with afatinib on H1975 (L858R/T790M double mutation) lung cancer cells. The combined treatment of HAD-B1 with afatinib inhibited the proliferation of H1975 cells in a dose-dependent manner compared with the treatment of afatinib or HAD-B1 alone. The combined treatment group significantly induced early apoptosis and cell cycle arrest of the cells compared with afatinib- or HAD-B1-treated control group. Profile analysis of cell cycle proteins in H1975 cells treated with the combination of HAD-B1 and afatinib using InnoPharmaScreen antibody microarray showed downregulation of pERK1/2 and upregulation of p16 in the cells. In vivo tumor growth assay in xenograft animal model of human H1975 lung cancer cells revealed that the mean tumor volume in the group treated with the combination of HAD-B1 and afatinib showed a significant reduction compared with the control groups. |
format | Online Article Text |
id | pubmed-6419252 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-64192522019-03-21 Inhibitory Effects of HangAmDan-B1 (HAD-B1) Combined With Afatinib on H1975 Lung Cancer Cell–Bearing Mice Kang, Hwa Jeong Kim, Jeehye Cho, Seong Hyeok Park, So-Jung Yoo, Hwa-Seung Kang, In-Cheol Integr Cancer Ther Research Article Epidermal growth factor receptor mutation-positive non–small cell lung cancer is cared for mainly by target therapeutics in the clinical treatment at present. We investigated the antitumor effect of HangAmDan-B1 (HAD-B1) combined with afatinib on H1975 (L858R/T790M double mutation) lung cancer cells. The combined treatment of HAD-B1 with afatinib inhibited the proliferation of H1975 cells in a dose-dependent manner compared with the treatment of afatinib or HAD-B1 alone. The combined treatment group significantly induced early apoptosis and cell cycle arrest of the cells compared with afatinib- or HAD-B1-treated control group. Profile analysis of cell cycle proteins in H1975 cells treated with the combination of HAD-B1 and afatinib using InnoPharmaScreen antibody microarray showed downregulation of pERK1/2 and upregulation of p16 in the cells. In vivo tumor growth assay in xenograft animal model of human H1975 lung cancer cells revealed that the mean tumor volume in the group treated with the combination of HAD-B1 and afatinib showed a significant reduction compared with the control groups. SAGE Publications 2019-03-13 /pmc/articles/PMC6419252/ /pubmed/30866688 http://dx.doi.org/10.1177/1534735419830765 Text en © The Author(s) 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Research Article Kang, Hwa Jeong Kim, Jeehye Cho, Seong Hyeok Park, So-Jung Yoo, Hwa-Seung Kang, In-Cheol Inhibitory Effects of HangAmDan-B1 (HAD-B1) Combined With Afatinib on H1975 Lung Cancer Cell–Bearing Mice |
title | Inhibitory Effects of HangAmDan-B1 (HAD-B1) Combined With Afatinib on H1975 Lung Cancer Cell–Bearing Mice |
title_full | Inhibitory Effects of HangAmDan-B1 (HAD-B1) Combined With Afatinib on H1975 Lung Cancer Cell–Bearing Mice |
title_fullStr | Inhibitory Effects of HangAmDan-B1 (HAD-B1) Combined With Afatinib on H1975 Lung Cancer Cell–Bearing Mice |
title_full_unstemmed | Inhibitory Effects of HangAmDan-B1 (HAD-B1) Combined With Afatinib on H1975 Lung Cancer Cell–Bearing Mice |
title_short | Inhibitory Effects of HangAmDan-B1 (HAD-B1) Combined With Afatinib on H1975 Lung Cancer Cell–Bearing Mice |
title_sort | inhibitory effects of hangamdan-b1 (had-b1) combined with afatinib on h1975 lung cancer cell–bearing mice |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419252/ https://www.ncbi.nlm.nih.gov/pubmed/30866688 http://dx.doi.org/10.1177/1534735419830765 |
work_keys_str_mv | AT kanghwajeong inhibitoryeffectsofhangamdanb1hadb1combinedwithafatinibonh1975lungcancercellbearingmice AT kimjeehye inhibitoryeffectsofhangamdanb1hadb1combinedwithafatinibonh1975lungcancercellbearingmice AT choseonghyeok inhibitoryeffectsofhangamdanb1hadb1combinedwithafatinibonh1975lungcancercellbearingmice AT parksojung inhibitoryeffectsofhangamdanb1hadb1combinedwithafatinibonh1975lungcancercellbearingmice AT yoohwaseung inhibitoryeffectsofhangamdanb1hadb1combinedwithafatinibonh1975lungcancercellbearingmice AT kangincheol inhibitoryeffectsofhangamdanb1hadb1combinedwithafatinibonh1975lungcancercellbearingmice |